Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage regenerative medicine company that entered the public markets through a business combination with Alpha Healthcare Acquisition Corp., a healthcare-focused blank-check company sponsored by Alpha Healthcare Partners. The company filed its S-1 registration statement on September 17, 2021, in connection with the de-SPAC transaction, with the combined entity listing on Nasdaq under the ticker HUMA. Humacyte develops bioengineered human acellular vessels targeting vascular repair, trauma surgery, and arteriovenous access applications. The SPAC vehicle completed its initial public offering in 2020 within the biotechnology and life sciences sector. Visit SpacDesk and sign up for full data, filings history, and deal analytics on HUMA and hundreds of other SPAC transactions.